The double-edged sword effect of NLRP3 inflammasome in cancer appears to be dependent on several factors, including its levels of expression, downstream effector molecules (i.e., IL-1β or IL-18), cancer type, stages of tumorigenesis as well as the potential presence of mutations affecting NLRP3 expression. Here, IL1B is linked to cancer.